Nouvelles immunotherapies du mélanome: mécanismes d'action, efficacité et prise en charge des toxicities [New melanoma immunotherapies: mechanisms of action, efficiency and management of toxicities]

Details

Serval ID
serval:BIB_5A4B24BBA8FE
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Nouvelles immunotherapies du mélanome: mécanismes d'action, efficacité et prise en charge des toxicities [New melanoma immunotherapies: mechanisms of action, efficiency and management of toxicities]
Journal
Revue medicale suisse
Author(s)
Moura B., Homicsko K., Berthod G., Cerottini J.P., Guggisberg D., Gaide O., Maillard M.H., Michielin O.
ISSN
1660-9379 (Print)
ISSN-L
1660-9379
Publication state
Published
Issued date
20/05/2015
Volume
11
Number
475
Pages
1108,1110-1114
Language
french
Notes
Publication types: English Abstract ; Journal Article ; Review
Publication Status: ppublish
Abstract
In recent years the therapy of metastatic melanoma has been revolutionized from a disease with very few efficient treatment options to one with access to multiple therapies which can impact on patient survival. Two main classes of therapies have been developed: 1. Immunotherapy by immune checkpoint inhibitors and 2. Small molecule inhibitors of the MAPK pathway. Immunotherapies achieved by either inhibition of CTLA-4 or the PD1/PD-Ll axes are impacting the overall survival in an important fraction of patients. In addition, the side effects of these immune therapy approaches require early detection by all the specialists involved as well as early management according to precise guidelines for optimal outcome.

Keywords
Drug-Related Side Effects and Adverse Reactions/therapy, Humans, Immunotherapy/adverse effects, Immunotherapy/methods, Immunotherapy/trends, Melanoma/immunology, Melanoma/therapy, Signal Transduction/immunology, Skin Neoplasms/immunology, Skin Neoplasms/therapy, Therapies, Investigational/adverse effects, Treatment Outcome, Vaccines/adverse effects
Pubmed
Create date
02/11/2017 12:02
Last modification date
20/08/2019 14:13
Usage data